The global gallbladder cancer market is witnessing significant growth owing to the growing prevalence of gallbladder polyps that can potentially lead to gallbladder cancer. Gallbladder cancer often arises from the pre-existing condition of gallbladder polyps, making regular screening and check-ups vital. Gallbladder cancer is not commonly diagnosed owing to non-specific clinical symptoms in early stages. However, the risk increases dramatically with age, with a majority of diagnoses occurring in individuals aged 70 years and above. The average age of diagnosis for gallbladder cancer is 65 years. The increasing average human lifespan and rapidly growing geriatric population globally is expected to drive the prevalence of gallbladder cancer in the coming years.
The global Gallbladder Cancer Market is estimated to be valued at US$ 1,607.47 Mn in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Get more insights on this topic: https://www.coherentmarketinsights.com/industry-reports/gallbladder-cancer-market
Market key trends:
One of the key trends in the gallbladder cancer market is the rise in research and development activities for novel targeted drug therapies. While surgery remains the primary treatment option for early-stage gallbladder cancer, the availability of effective pharmacological therapies is limited for late-stage and metastatic gallbladder cancer. Companies are conducting clinical trials evaluating drugs such as immunotherapies, chemotherapy regimens, and molecular targeted therapies. For instance, Histogen Inc. is developing HTG-110, an epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitor for the treatment of advanced biliary tract cancers including gallbladder cancer. Positive results from ongoing and planned clinical studies can provide safe and effective non-surgical options to management of late-stage gallbladder cancer. This is expected to significantly improve patient outcomes and quality of life in the long run.
Porter’s Analysis
Threat of new entrants: The gallbladder cancer market requires high capital investment for RD, clinical trials, and manufacturing facilities. This poses entry barriers for new players.
Bargaining power of buyers: There are only a few approved treatment options available for gallbladder cancer. This gives pharmaceutical companies higher bargaining power over buyers.
Bargaining power of suppliers: The suppliers of raw materials and production machinery have moderate bargaining power due to the presence of substitute suppliers.
Threat of new substitutes: Alternative treatment options for gallbladder cancer include surgery, chemotherapy, and radiation therapy. This poses a moderate threat of substitutes.
Competitive rivalry: The market comprises large pharmaceutical companies and small biotech startups. The competition focuses on developing novel drugs and combination therapies.
Key Takeaways
The global gallbladder cancer market is expected to witness high growth over the forecast period owing to the rising prevalence of gallbladder cancer worldwide.
The high availability of advanced healthcare infrastructure and presence of major market players in the region are supporting market growth. North America is expected to lead the global gallbladder cancer market during the forecast period. This is attributed to the growing patient population, developed healthcare infrastructure, and rising healthcare spending in the region.
Key players
Key players operating in the gallbladder cancer market are Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, HCell Inc., Follica, Inc. and Ranbaxy Laboratorie.
